Intracranial pressure (ICP) is the pressure inside the skull, which can be measured in the ventricular system through a thin catheter inserted into the brain via burr holes. It is measured in millimeters of mercury (mm Hg). The ICP is normally 7 mmHg and varies with age, gender, posture, and respiration. It plays a very important role in maintaining the health and viability of the central nervous system. High intracranial pressure (above 20 mm Hg) has been linked to a number of neurological conditions including increased headaches, hydrocephalus, brain herniation, and even death. Elevated ICP is mostly caused by increased production and/or reduced absorption of cerebrospinal fluid (CSF). It is also a common symptom of abnormal intracranial circulation of blood, which can be caused by cerebral ischemia, stroke, and brain tumors. In the medical profession, it is considered important to monitor and manage ICP in order to avoid these complications and to ensure adequate oxygenation of the brain. ICP is monitored with a device called an intracranial pressure monitor, which is placed directly into the brain and monitored continuously. An individual’s ICP can also be monitored by a continuous EEG or ICP transducer. Managing ICP involves controlling factors that could possibly lead to increased ICP, such as maintaining adequate hydration and positioning the patient. It also involves medicines to reduce the amount of CSF produced by the body. In order to reduce the risk of adverse effects, a physician must take into account any other underlying conditions that the patient might have, as some treatments might be contraindicated. In conclusion, intracranial pressure is an extremely important part of maintaining a healthy central nervous system, and knowledge of this pressure is essential to providing the best patient care. The ability to accurately measure and manage it can reduce the risk of serious complications and ensure the highest quality of life.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States